The pathogenesis of myasthenia gravis involves a humorally mediated autoimmune attack directed against acetylcholine receptors of skeletal muscles. Antibodies against acetylcholine receptors are detected in the serum of more than 80 per cent of patients, but the antibody titers correspond poorly with the severity of disease. To distinguish between antibody titers and antibody activity, we measured the ability of serum immunoglobulin from 49 patients to induce accelerated degradation or blockade of the binding sites of acetylcholine receptors, using a mammalian skeletal-muscle tissue-culture system. Immunoglobulin from 41 of 45 patients tested (91 per cent) increased the rate of degradation of acetylcholine receptors, and the relative increase in the degradation rate corresponded closely (P less than 0.001) with clinical status. Immunoglobulin from 42 of 48 patients tested (88 per cent) produced blockade of receptors, and the extent of the blockade also corresponded with clinical status (P less than 0.001). An index of the combined activities of the immunoglobulin in accelerating degradation and producing blockade of acetylcholine receptors was elevated in 43 of 44 patients (98 per cent) whose immunoglobulins were tested for both activities; this index predicted the patients' clinical status significantly better (P less than 0.001) than either measure alone. This finding suggests that the functional ability of antibodies to decrease the number of available acetylcholine receptors by these two mechanisms is clinically relevant in the pathogenesis of myasthenia gravis.
This article has been cited by other articles:
Zhou, Y., Gong, B., Lin, F., Rother, R. P., Medof, M. E., Kaminski, H. J.
(2007). Anti-C5 Antibody Treatment Ameliorates Weakness in Experimentally Acquired Myasthenia Gravis. J. Immunol.
179: 8562-8567
[Abstract][Full Text]
Leite, M. I., Jones, M., Strobel, P., Marx, A., Gold, R., Niks, E., Verschuuren, J. J.G.M., Berrih-Aknin, S., Scaravilli, F., Canelhas, A., Morgan, B. P., Vincent, A., Willcox, N.
(2007). Myasthenia Gravis Thymus: Complement Vulnerability of Epithelial and Myoid Cells, Complement Attack on Them, and Correlations with Autoantibody Status. Am. J. Pathol.
171: 893-905
[Abstract][Full Text]
Zinman, L., Ng, E., Bril, V.
(2007). IV immunoglobulin in patients with myasthenia gravis: A randomized controlled trial. Neurology
68: 837-841
[Abstract][Full Text]
Natarajan, N., Weinstein, R.
(2005). Therapeutic Apheresis in Neurology Critical Care. J Intensive Care Med
20: 212-225
[Abstract]
Poea-Guyon, S., Christadoss, P., Le Panse, R., Guyon, T., De Baets, M., Wakkach, A., Bidault, J., Tzartos, S., Berrih-Aknin, S.
(2005). Effects of Cytokines on Acetylcholine Receptor Expression: Implications for Myasthenia Gravis. J. Immunol.
174: 5941-5949
[Abstract][Full Text]
Kothari, M. J.
(2004). Myasthenia Gravis. JAOA: Journal of the American Osteopathic Association
104: 377-384
[Abstract][Full Text]
Stacy, S., Gelb, B. E., Koop, B. A., Windle, J. J., Wall, K. A., Krolick, K. A., Infante, A. J., Kraig, E.
(2002). Split Tolerance in a Novel Transgenic Model of Autoimmune Myasthenia Gravis. J. Immunol.
169: 6570-6579
[Abstract][Full Text]
Reyes-Reyna, S., Stegall, T., Krolick, K. A.
(2002). Muscle Responds to an Antibody Reactive with the Acetylcholine Receptor by Up-Regulating Monocyte Chemoattractant Protein 1: A Chemokine with the Potential to Influence the Severity and Course of Experimental Myasthenia Gravis. J. Immunol.
169: 1579-1586
[Abstract][Full Text]
Chaudhry, V., Cornblath, D. R., Griffin, J. W., O'Brien, R., Drachman, D. B.
(2001). Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases. Neurology
56: 94-96
[Abstract][Full Text]
Dalakas, M. C., Fujii, M., Li, M., McElroy, B.
(2000). The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology
55: 1531-1535
[Abstract][Full Text]
ARAGA, S., XU, L., NAKASHIMA, K., VILLAIN, M., BLALOCK, J. E.
(2000). A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help. FASEB J.
14: 185-196
[Abstract][Full Text]
Bongioanni, P., Ricciardi, R., Romano, M. R.
(1999). T-Lymphocyte Interferon-{gamma} Receptor Binding in Patients With Myasthenia Gravis. Arch Neurol
56: 933-938
[Abstract][Full Text]
Balasa, B., Deng, C., Lee, J., Bradley, L. M., Dalton, D. K., Christadoss, P., Sarvetnick, N.
(1997). Interferon gamma (IFN-gamma ) Is Necessary for the Genesis of Acetylcholine Receptor-induced Clinical Experimental Autoimmune Myasthenia gravis in Mice. JEM
186: 385-391
[Abstract][Full Text]
Drachman, D. B.
(1994). Myasthenia Gravis. NEJM
330: 1797-1810
[Full Text]
Stricker, R. B., Kwiatkowska, B. J., Habis, J. A., Kiprov, D. D.
(1993). Myasthenic Crisis: Response to Plasmapheresis Following Failure of Intravenous {gamma}-Globulin. Arch Neurol
50: 837-840
[Abstract]
Harley, J., Reichlin, M, Arnett, F., Alexander, E., Bias, W., Provost, T.
(1986). Gene interaction at HLA-DQ enhances autoantibody production in primary Sjogren's syndrome. Science
232: 1145-1147
[Abstract]
